Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson’s drug FLZ after multi-dose in cynomolgus monkeys

References

• Bao XQ, Kong XC, Qian C, Zhang D. 2012. FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson’s disease models. Neuroscience. 202:396–404. doi: 10.1016/j.neuroscience.2011.11.036.
   PubMed Web of Science ®Google Scholar
• Bao XQ, Wang L, Yang HY, Hou LY, Wang QS, Zhang D. 2020. Induction of glial cell line-derived neurotrophic factor by the squamosamide derivative FLZ in astroglia has neuroprotective effects on dopaminergic neurons. Brain Res Bull. 154:32–42. doi: 10.1016/j.brainresbull.2019.10.008.
   PubMed Web of Science ®Google Scholar
• Bao XQ, Wu LY, Wang XL, Sun H, Zhang D. 2015. Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson’s disease. Naunyn-Schmiedeberg’s Arch Pharmacol. 388(5):549–556. doi: 10.1007/s00210-015-1094-5.
   Google Scholar
• Chia SJ, Tan EK, Chao YX. 2020. Historical perspective: models of Parkinson’s disease. Int J Mol Sci. 21(7):2464.
   Web of Science ®Google Scholar
• Cui C, Chen R, Jiang J, Liu R, Wang W, Zhao Q, Hu P. 2019. Simultaneous determination of FLZ and its metabolite (M1) in human plasma and urine by UHPLC-MS/MS: application to a pharmacokinetic study. J Pharm Biomed Anal. 164:32–40. doi: 10.1016/j.jpba.2018.10.018.
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. 2003. Parkinson’s disease: mechanisms and models. Neuron. 39(6):889–909. doi: 10.1016/s0896-6273(03)00568-3.
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P. 1995. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther. 57(5):508–517. doi: 10.1016/0009-9236(95)90035-7.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Sherer T, Okun MS, Bloem BR. 2018. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 8(s1):S3–S8. doi: 10.3233/JPD-181474.
   PubMedGoogle Scholar
• Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. 2015. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 14(6):625–639. doi: 10.1016/S1474-4422(15)00007-1.
   PubMed Web of Science ®Google Scholar
• Feng W, Wei H, Liu GT. 2005. Pharmacological study of the novel compound FLZ against experimental Parkinson’s models and its active mechanism. Mol Neurobiol. 31(1–3):295–300. doi: 10.1385/MN:31:1-3:295.
   PubMed Web of Science ®Google Scholar
• Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. 2017. Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 23(5 Suppl):S83–S92.
   PubMed Web of Science ®Google Scholar
• Gao Y, Shao J, Jiang Z, Chen J, Gu S, Yu S, Zheng K, Jia L. 2014. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Discov Today. 19(3):326–340. doi: 10.1016/j.drudis.2013.11.020.
   PubMed Web of Science ®Google Scholar
• Hou J, Qu F, Wu C, Ren Q, Zhang J. 2012. Quantitative determination and pharmacokinetic study of the novel anti-Parkinson’s disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 66:232–239. doi: 10.1016/j.jpba.2012.03.001.
   PubMed Web of Science ®Google Scholar
• Leuratti C, Sardina M, Ventura P, Assandri A, Müller M, Brunner M. 2013. Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology. 92(3–4):207–216. doi: 10.1159/000354805.
   PubMed Web of Science ®Google Scholar
• Li LB, Zhang JL, Wang YX, Wei HL, Liu GT. 2008. Establishment of a HPLC method for preclinical pharmacokinetic study of the novel anti-Parkinson’s disease candidate drug FLZ in rats. Biomed Chromatogr. 22(8):867–872. doi: 10.1002/bmc.1004.
   PubMed Web of Science ®Google Scholar
• Liu Q, Hou J, Chen X, Liu G, Zhang D, Sun H, Zhang J. 2014. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson’s disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models. PLOS One. 9(7):e102442. doi: 10.1371/journal.pone.0102442.
   PubMed Web of Science ®Google Scholar
• Shang J, Ma S, Zang C, Bao X, Wang Y, Zhang D. 2021. Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson’s disease treatment. Acta Pharm Sin B. 11(5):1213–1226. doi: 10.1016/j.apsb.2021.01.009.
   PubMed Web of Science ®Google Scholar
• Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD. 2003. Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos. 31(3):326–333. doi: 10.1124/dmd.31.3.326.
   PubMed Web of Science ®Google Scholar
• Soulele K, Karalis V. 2019. On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. Xenobiotica. 49(4):446–456. doi: 10.1080/00498254.2018.1463117.
   PubMed Web of Science ®Google Scholar
• Takashima T, Shingaki T, Katayama Y, Hayashinaka E, Wada Y, Kataoka M, Ozaki D, Doi H, Suzuki M, Ishida S, et al. 2013. Dynamic analysis of fluid distribution in the gastrointestinal tract in rats: positron emission tomography imaging after oral administration of nonabsorbable marker, [(18)F]deoxyfluoropoly(ethylene glycol). Mol Pharm. 10(6):2261–2269. doi: 10.1021/mp300469m.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Wenning G, Poewe W. 2006. The diagnosis of Parkinson’s disease. Lancet Neurol. 5(1):75–86. doi: 10.1016/S1474-4422(05)70285-4.
   PubMed Web of Science ®Google Scholar
• Wang T, Wang H, Chen R, Jiang J, Zhao Q, Hu P. 2020. A UHPLC-MS/MS method to determine FLZ major active metabolites in human plasma: application to a pharmacokinetic study. Bioanalysis. 12(9):583–596. doi: 10.4155/bio-2020-0033.
   PubMed Web of Science ®Google Scholar
• Wollmer E, Klein S. 2022. Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson’s disease patients. Eur J Pharm Biopharm. 180:101–118. doi: 10.1016/j.ejpb.2022.09.015.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li F, Ning J, Peng R, Shang J, Liu H, Shang M, Bao XQ, Zhang D. 2021. Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-kappaB pathway through microbiota-gut-brain axis. Acta Pharm Sin B. 11(9):2859–2879. doi: 10.1016/j.apsb.2021.03.020.
   PubMed Web of Science ®Google Scholar